Neurocrine Biosciences Net Worth

Neurocrine Biosciences Net Worth Analysis

Neurocrine Biosciences Target Price Consensus

Neurocrine Biosciences Target Price Projection

Neurocrine Biosciences' current and average target prices are 143.03 and 133.45, respectively. The current price of Neurocrine Biosciences is the price at which Neurocrine Biosciences is currently trading. On the other hand, Neurocrine Biosciences' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Neurocrine Biosciences and the information provided on this page.

Know Neurocrine Biosciences' Top Institutional Investors

Note, although Neurocrine Biosciences' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow Neurocrine Biosciences' market capitalization trends

The company currently falls under 'Large-Cap' category with a current market capitalization of 13.83 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Neurocrine Biosciences's market, we take the total number of its shares issued and multiply it by Neurocrine Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Project Neurocrine Biosciences' profitablity

The company has Profit Margin (PM) of 0.13 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.29 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.29.

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Evaluate Neurocrine Biosciences' management efficiency

Neurocrine Biosciences has return on total asset (ROA) of 0.0878 % which means that it generated a profit of $0.0878 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1268 %, meaning that it created $0.1268 on every $100 dollars invested by stockholders. Neurocrine Biosciences' management efficiency ratios could be used to measure how well Neurocrine Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.08 in 2024. Return On Capital Employed is likely to rise to 0.10 in 2024. At this time, Neurocrine Biosciences' Asset Turnover is fairly stable compared to the past year.

Neurocrine Biosciences Corporate Filings

Neurocrine Biosciences time-series forecasting models is one of many Neurocrine Biosciences' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Neurocrine Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Neurocrine Biosciences Earnings Estimation Breakdown

The calculation of Neurocrine Biosciences' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Neurocrine Biosciences is estimated to be 1.01 with the future projection ranging from a low of 0.18 to a high of 1.77. Please be aware that this consensus of annual earnings estimates for Neurocrine Biosciences is based on EPS before non-recurring items and includes expenses related to employee stock options.

Neurocrine Biosciences Earnings Projection Consensus

Neurocrine Biosciences Earnings per Share Projection vs Actual

Actual Earning per Share of Neurocrine Biosciences refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Neurocrine Biosciences predict the company's earnings will be in the future. The higher the earnings per share of Neurocrine Biosciences, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Neurocrine Biosciences Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Neurocrine Biosciences, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Neurocrine Biosciences should always be considered in relation to other companies to make a more educated investment decision.

Neurocrine Quarterly Analyst Estimates and Surprise Metrics

Be your own money manager

Our tools can tell you how much better you can do entering a position in Neurocrine Biosciences without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Neurocrine Biosciences Corporate Directors

Neurocrine Biosciences corporate directors refer to members of a Neurocrine Biosciences board of directors. The board of directors generally takes responsibility for the Neurocrine Biosciences' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Neurocrine Biosciences' board members must vote for the resolution. The Neurocrine Biosciences board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.

How to buy Neurocrine Stock?

The net worth of Neurocrine Biosciences is the difference between its total assets and liabilities. Neurocrine Biosciences' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Neurocrine Biosciences' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Neurocrine Biosciences' net worth can be used as a measure of its financial health and stability which can help investors to decide if Neurocrine Biosciences is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Neurocrine Biosciences stock.

Already Invested in Neurocrine Biosciences?

When determining whether Neurocrine Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neurocrine Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neurocrine Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neurocrine Biosciences Stock:

How To Invest In Neurocrine Details

Is Neurocrine Stock a good investment? Details

What is Neurocrine Biosciences' Net Worth? Details

Largest Biotechnology Companies View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies View

Complementary Tools for Neurocrine Stock analysis

Altman Z Score Details

Piotroski F Score Details

Beneish M Score Details

Financial Analysis Details

Buy or Sell Advice Details

Earnings Projections Details